Dr. Reddy’s Laboratories Ltd. anticipates its generic anti-obesity drug will drive growth in the six months leading up to March. This projection comes after the company addresses an impurity issue concerning the active pharmaceutical ingredient (API) and plans to resume supply in early November.

The company experienced a setback when it had to halt production of its weight-loss drug due to the impurity. This interruption impacted its sales and growth trajectory. However, with the resolution of the API issue, Dr. Reddy's is poised to re-enter the market and capitalize on the significant demand for effective weight-management solutions.

Analysts suggest that the successful relaunch of this drug could significantly contribute to Dr. Reddy's financial performance in the upcoming fiscal year. The market for weight-loss medications is expanding rapidly, and the company aims to capture a substantial share with its affordable generic alternative. The resolution of the impurity and subsequent resumption of supply are critical for Dr. Reddy's to meet market expectations and regain momentum.